A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)

Korábbi kezelés

• Anticancer and/or investigational therapy within the past 30 days or 5 half-lives
• Allogeneic stem cell transplantation within the past 6 months, or ASCT within 3 months before C1D1
• Previous treatment with CD19-targeted therapy or PI3K inhibitors

Más betegség

• Clinically significant cardiac disease
• Other malignancy within the past 3 years
• Active graft-versus-host disease
• Stroke or intracranial hemorrhage within the past 6 months
• Chronic or current active infectious disease
• Positive virus serology for HCV, HBV, HIV

Egyéb

• Any other histological type of lymphoma
• Primary or secondary CNS lymphoma
• Currently pregnant or breastfeeding

• Histologically confirmed R/R B-cell malignancy: DLBCL (THRLBCL, EBV-positive DLBCL of the elderly, Grade 3b FL, HGBL with MYC and BCL2 and/or BCL6 rearrangements, transformed lymphoma); MCL ((with cyclin D1 overexpression or t(11;14); FL (Grade 1, 2, 3a); MZL (extranodal, nodal, splenic) ; CLL, or SLL
• Willingness to undergo biopsy
• At least 2 prior systemic treatment regimens, including prior treatment with an anti-CD20 antibody (all cohorts) or prior treatment with a BTK inhibitor (CLL/SLL)
• Relapsed, progressive, or refractory NHL or CLL
• For NHL/SLL: Radiographically measurable nodal or extranodal disease (all cohorts except CLL)
• ECOG-PS 0 - 2
• LVEF ≥ 50%
• Adequate renal, hepatic, bone marrow function